Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R
Maribel starts every patient at a conservative dose and titrates upward based on tolerance and response
From microRNA to protein, linking the neurotrophic hypothesis of depression to the Wistar-Kyoto rat
They reduced microbial loads of E
To view a copy of this licence, visit About this article Cite this article Shah, H., Parisi, R., Mukherjee, E
FDA-APPROVED INDICATIONS Type 2 diabetes As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus Limitations of use: has not been studied in patients with a history of pancreatitis TYPE 2 DIABETES RCT SURPASS-2 trial - Tirzepatide vs Semaglutide in Patients with Type 2 Diabetes, NEJM (2021) [PubMed abstract] The SURPASS-2 trial enrolled 1879 adults with type 2 diabetes who were inadequately controlled with metformin at a dose of at least 1500 mg per day Main inclusion criteria Age 18 years T2DM uncontrolled with metformin at 1500 mg/day A1C of 7 - 10.5% BMI 25 and stable for 3 months Main exclusion criteria Type 1 diabetes GFR 50 ng/L
